News

Cambridge Cognition secures Innovate UK grant to collect multimodal data with a large patient sample in the Bio-Hermes 2 project

Cambridge, UK—10 July 2024: Cambridge Cognition, a leading provider of digital health solutions for brain health assessments has been included in the Bio-Hermes 2 project for its voice and touch-screen cognitive assessments, funded by the UK’s innovation agency, Innovate UK.  The Bio-Hermes 2 trial, led by the Global Alzheimer’s Platform Foundation (GAP), aims to determine […]

Cambridge Cognition secures Innovate UK grant to collect multimodal data with a large patient sample in the Bio-Hermes 2 project Read More »

New partnership with the University of Essex to strengthen CANTAB® normative data offering

We’ve joined forces with ESSEXLab at the Centre for Behavioural Science (CBS), University of Essex, to gather normative data from latency-based and rater-scored tasks like our Reaction Time (RTI) task and Verbal Recognition Memory (VRM). This partnership will significantly enrich our normative offerings further and provide robust benchmarks, demonstrating the sensitivity in CANTAB endpoints. Our

New partnership with the University of Essex to strengthen CANTAB® normative data offering Read More »

Cambridge Cognition and The Michael J. Fox Foundation to employ digital cognitive assessments in unraveling the mysteries of Parkinson’s disease

Cambridge, UK – 30 April 2024: Cambridge Cognition, a leading provider of digital health solutions for brain health assessment, has announced that The Michael J. Fox Foundation for Parkinson’s Disease Research will incorporate its CANTAB® cognitive assessments into the Parkinson’s Progression Markers Initiative (PPMI).  The landmark initiative will use Cambridge Cognition’s technology to identify the cognitive

Cambridge Cognition and The Michael J. Fox Foundation to employ digital cognitive assessments in unraveling the mysteries of Parkinson’s disease Read More »

Cambridge Cognition spin-out Monument Therapeutics accesses £1.5m for schizophrenia clinical development

Cambridge, UK – 23 April 2024: Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that Monument Therapeutics Limited (“Monument”) a precision neuroscience company spun-out from, and partly owned by Cambridge Cognition, has completed a £1.0 million fundraise and announced a further £0.5 million grant

Cambridge Cognition spin-out Monument Therapeutics accesses £1.5m for schizophrenia clinical development Read More »

Cambridge Cognition strengthens senior management team to deliver growth

Cambridge, UK – 10 April 2024: Cambridge Cognition, a leader in digital health solutions for brain health assessment, has announced the appointments of Alex Livingstone-Learmonth as Chief Commercial Officer and Annabelle Miles as Head of Marketing. These strategic additions mark a significant step as the Company continues strengthening its senior leadership team in pursuit of

Cambridge Cognition strengthens senior management team to deliver growth Read More »

Cambridge Cognition announces scientific advisory board

Cambridge, UK – 21 March 2024: Cambridge Cognition, a leader in digital health solutions for brain health assessment, announces the formation of a Scientific Advisory Board (SAB). This expert board will provide scientific guidance and valuable market insights, primarily focusing on addressing emerging trends such as the integration of blood-based biomarkers and the collaborative possibilities

Cambridge Cognition announces scientific advisory board Read More »

Cambridge Cognition and ActiGraph announce partnership to accelerate central nervous system trials

by ActiGraph PENSACOLA, FL, February 20, 2024 – ActiGraph and Cambridge Cognition, leading providers of wearable digital health technologies and CNS assessments, respectively, announced a new strategic partnership to deliver a broad suite of assessments to provide a fully-rounded view of mental and physical capabilities. The companies’ technologies have been used together by top 20

Cambridge Cognition and ActiGraph announce partnership to accelerate central nervous system trials Read More »

Cambridge Cognition’s Global Teams Unite for Mental Health Causes! 

Cambridge Cognition unveils strategic partnership for Chinese market expansion Cambridge Cognition is pleased to announce an expansion in the Chinese market through a strategic partnership with Luca Healthcare Limited, a category leader in digital screening, treatment and management tools in China. Cambridge Cognition has signed an exclusive licencing agreement with Luca Healthcare

Cambridge Cognition’s Global Teams Unite for Mental Health Causes!  Read More »

Launch of automated quality assurance for clinical trials

News Back to resource centre 24 October 2023 Launch of automated quality assurance for clinical trials Cambridge Cognition (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce the launch today of AQUA, the Company’s automated quality assurance solution for central nervous system (“CNS”) clinical trials that is powered

Launch of automated quality assurance for clinical trials Read More »

2023 CANTAB Research Grant winners announced

Cambridge Cognition unveils strategic partnership for Chinese market expansion Cambridge Cognition is pleased to announce an expansion in the Chinese market through a strategic partnership with Luca Healthcare Limited, a category leader in digital screening, treatment and management tools in China. Cambridge Cognition has signed an exclusive licencing agreement with Luca Healthcare

2023 CANTAB Research Grant winners announced Read More »

Scroll to Top